Objectives: 16S rRNA methyltransferases are an emerging mechanism conferring high-level resistance to clinically relevant aminoglycosides and have been associated with important mechanisms such as NDM-1. We sought genes encoding these enzymes in isolates highly resistant (MIC .200 mg/L) to gentamicin and amikacin from an Indian hospital and we additionally screened for the novel RmtF enzyme in 132 UK isolates containing NDM.
Introduction
Aminoglycosides are considered to be critically important antibiotics by the World Health Organization. 1 Resistance is frequently mediated by aminoglycoside-modifying enzymes that are able to acetylate, phosphorylate or adenylate the antibiotic molecule. 2 Recently, methylation of the aminoacyl site of the 16S rRNA has been described as an acquired high-level resistance mechanism to clinically important aminoglycosides such as amikacin, tobramycin and gentamicin. 3 Since 2003, eight 16S rRNA methyltransferase genes-armA, rmtA, rmtB, rmtC, rmtD, rmtE, rmtF and npmA-have been identified in several species of pathogenic bacteria worldwide, 4 -6 being reported in most cases from human clinical isolates. The genes encoding these determinants are usually borne by mobile genetic elements and have been associated with mechanisms conferring resistance to other antibiotic classes, such as Qnr, 7 acquired AmpC 7 or extended-spectrum b-lactamases (ESBLs). 8 -10 Recently these methyltransferases have been found in association with the NDM-1 determinant that was first described for Swedish isolates obtained from a patient of Indian origin. 11 -15 The recent appearance of multidrug-resistant bacteria with NDM-1 and other emerging resistance determinants such as the 16S rRNA methyltransferases is becoming an increasing clinical and public health threat.
This study was initially designed to determine the prevalence of 16S rRNA methyltransferases among clinical Enterobacteriaceae isolated in a hospital in India and their association with the emerging NDM-type carbapenemase. The novel 16S rRNA methyltransferase RmtF was evident in several Indian isolates and we therefore carried out an extensive screening for the rmtF gene in NDM-producing Enterobacteriaceae from the UK.
Methods

Bacterial isolates and antimicrobial susceptibility testing
A total of 1000 consecutive clinical Enterobacteriaceae strains recovered at the Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow, India, were analysed for their ability to grow on brain heart infusion (BHI) agar containing both 200 mg/L amikacin and 200 mg/L gentamicin. These strains were collected during 2010 (months of June, September, October and December) and January 2011. Clinical samples were urine, pus, sputum, CSF and blood. The Sanjay Gandhi Postgraduate Institute of Medial Sciences is an 800 bed tertiary care and referral hospital that draws patients from most of the states of northern India with the majority from the states of Uttar Pradesh and Bihar. All the isolates were recovered from patients admitted to the hospital in different medical and surgical disciplines. The MICs of ampicillin, amoxicillin/ clavulanic acid, cefotaxime, cefotaxime/clavulanic acid, aztreonam, imipenem, imipenem/EDTA, meropenem, ciprofloxacin, tobramycin, amikacin, gentamicin, tigecycline and colistin were determined for aminoglycoside-resistant isolates by BSAC agar dilution methodology and interpreted according to BSAC version 10.2 criteria.
In addition, 132 NDM-producing Enterobacteriaceae received at the Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, Health Protection Agency, UK, between 2009 and 2011 were screened for the presence of the newly discovered rmtF gene.
PCR and strain typing
PCRs for genes encoding the 16S methyltransferases (armA and rmtA-F), CTX-M ESBLs and NDM-type carbapenemase were carried out using primers listed in Table 1 and lysed cells as DNA template. A multiplex PCR was performed for the detection of acquired AmpC genes as previously described. 20 Sequences of the designed primers for the study of the rmtF genetic environment can be found in Table 1 . The phylogenetic groups of Escherichia coli isolates were determined as previously described. 21 Relatedness among the isolates was assessed by PFGE. Genomic DNA was embedded in agarose blocks and digested with XbaI (Roche Diagnostics, Mannheim, Germany). PFGE was carried out on a CHEF-DR III device (Bio-Rad, Hercules, CA, USA) for 30 h at 6 V/cm 2 and 128C with an initial pulse time of 5 s and a final pulse time of 35 s. A dendrogram of strain relatedness was constructed with BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) for the Klebsiella pneumoniae isolates.
DNA analysis and manipulation
Cloning experiments were carried out by digesting plasmid DNA with EcoRI restriction enzyme and ligating the resulting fragments into pUC19 vector. The ligation mixture was transformed into DH5a cells, which were then plated on agar containing ampicillin (50 mg/L) and gentamicin (10 mg/L). A CloneJET PCR cloning kit (Fermentas International Inc.) was used to clone rmtF along with its promoter region, previously determined with the Softberry online tool.
Plasmid characterization
Plasmid DNA was extracted from clinical isolates using a Plasmid Midi kit (Qiagen Inc., Chatsworth, CA, USA). Transformation experiments were conducted with Alpha-Select Electrocompetent cells (Bioline, London, UK) following the manufacturer's instructions. Plasmids were classified according to their incompatibility group using a PCR-based replicon typing kit (Diatheva, Fano, Italy). Plasmid multilocus sequence typing (pMLST) was used to further characterize IncN plasmids. 22 In order to determine plasmid size, agarose blocks containing total DNA were digested with S1 nuclease (Promega, Madison, WI, USA) following the manufacturer's instructions. Blocks were then loaded into a 1% agarose gel and PFGE was performed as previously described. 16 Analysis of bacterial rRNA by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry Total rRNA was extracted from ribosomal particles isolated from rmtF-bearing transformant E. coli BB1284. 23 The 16S rRNA sequence from C1378-G1432 was protected by hybridization to a complementary deoxyoligonucleotide and the unhybridized RNA was digested with mung bean nuclease (NE Biolabs, Ipswich, MA, USA) and RNase A (Sigma-Aldrich, St Louis, MO, USA) as previously described. 24 The rRNA fragment was isolated by gel electrophoresis 24, 25 and digested overnight The program m/z (Proteometrics Ltd, New York, NY, USA) was used for interpreting the spectra.
Results
16S rRNA methyltransferases are highly prevalent among clinical isolates in India
One-hundred-and-forty (14%) of 1000 consecutive clinical isolates of Enterobacteriaceae from the Sanjay Gandhi Postgradu- Figure 1 . (a) Three-dimensional structure of the 30S ribosomal subunit. 34 Yellow and orange represent proteins and 16S rRNA, respectively. Helix 44 is shown in red and the enlarged view shows the aminoglycoside binding pocket. (b) The theoretical monoisotopic masses of RNase T1 digestion products of trinucleotides and larger from the E. coli 16S rRNA sequence C1378-G1432. (c) MALDI mass spectrometry spectrum of this region from E. coli expressing rmtF, showing the empirically measured masses. Methylation at G1405 prevents RNase T1 cleavage at this nucleotide and gives rise to the longer fragments at m/z 4467 and 4481. The m/z 4467 fragment lacks the intrinsic methylation at C1407, 35 which could be partially obstructed by the action of RmtF.
RmtF and NDM in India and the UK 1545 JAC .200 mg/L) to the 4,6-disubstituted 2-deoxystreptamine aminoglycosides, such as gentamicin, amikacin and tobramycin. 5, 6 Using MALDI mass spectrometry we found that RmtF confers high-level aminoglycoside resistance by adding a methyl group at position G1405 of the bacterial 16S rRNA (Figure 1 ).
rmtF detected in diverse Enterobacteriaceae in India and the UK
The 140 Indian isolates were screened for the rmtF gene using PCR (see Table 1 for rmtF-specific primer sequences). A total of 34 isolates were found to carry rmtF; these comprised 17 K. pneumoniae, 10 E. coli (six of them belonging to the phylogenetic group B2 related with virulent extra-intestinal strains), 3 C. freundii and 4 E. cloacae isolates ( Table 2 ). The 17 K. pneumoniae isolates had 15 different PFGE profiles using a cut-off at 85% genetic similarity. Two pairs of isolates, collected consecutively, shared an identical profile. The first pair was isolated from sputum and pus and the second pair was isolated from pus and urine; each isolate was from a different patient and thus represents possible cross-infection. Following the Tenover et al. 27 PFGE interpretation, four E. coli isolates were Hidalgo et al.
indistinguishable (no band differences), and compared with them the six other E. coli were unrelated (seven or fewer fragment differences). Of these six, two were identical, making a total of six different profiles. Two E. cloacae out of four shared identical PFGE patterns, while all the C. freundii isolates were unrelated. More NDM-positive Enterobacteriaceae have been detected in the UK than any other European country, 28 and because 20 of 34 rmtF-positive Indian isolates also harboured bla NDM , we screened 132 NDM-producing isolates from the UK for rmtF and other 16S rRNA methyltransferases. The armA, rmtB or rmtC genes were detected in 44 (33%), 1 (0.8%) and 47 (36%) isolates, respectively. Eighteen (14%) isolates harboured both armA and rmtC, while 1 (0.8%) harboured armA and rmtB. Six (5%) UK isolates, all K. pneumoniae harboured rmtF (Table 2) . These had been isolated from blood, urine or rectal swabs from patients in different RmtF and NDM in India and the UK 1547 JAC hospitals across the UK. PFGE showed that these UK isolates were distinct from each other (≤85% of genetic similarity) except for three of them sharing 88% genetic similarity. Most of these isolates were unrelated to the rmtF-positive K. pneumoniae isolates from India; however, one UK isolate (H113840625) was closely related (88% genetic similarity) with an Indian isolate (BB1269) (data not shown).
Analysis of plasmids encoding RmtF
The rmtF gene was transferred by electroporation to an E. coli recipient from 31 of 40 isolates; transformants could not be obtained for 9 Indian isolates. Plasmid rep typing revealed that most rmtF-bearing plasmids (in 19 isolated strains, from India and the UK) were untypeable. However, rmtF was located on IncN plasmids in five E. coli, three K. pneumoniae and one C. freundii, all from India, and on IncR plasmids in three K. pneumoniae from India ( Table 2 ). All of the IncN plasmids were analysed by pMLST and belonged to a new sequence type, ST14.
To characterize the genetic environment of rmtF, two PCR assays were developed (Table 1 ) to amplify regions of 1.2 and 1.5 kb upstream and downstream of rmtF, respectively. Twenty-one (52.5%) isolates of different species and bearing rmtF on distinct plasmid backbones were positive for both PCR products and 16 (40%) were positive only for the upstream fragment. Three isolates were negative in both PCR assays.
RmtF is associated with emerging resistance mechanisms, including NDM carbapenemase Antibiotic susceptibility profiles for the 34 Indian and 6 UK RmtF-positive isolates revealed phenotypes compatible with other co-resident resistance determinants (Table 3) . Furthermore, PCR screening showed that in several cases RmtF was co-resident in the same isolate with a second 16S rRNA methyltransferase-ArmA, RmtB or RmtC (Figure 2) .
Twenty of the 34 Indian RmtF isolates (59%) were NDM positive; these were not selected on the basis of carbapenem resistance. The six UK RmtF isolates were detected during targeted screening of NDM-positive isolates from 2009 (one isolate), 2010 (one isolate) and 2011 (four isolates). As shown by the S1-PFGE technique performed with the transformants, the NDM gene and rmtF were genetically linked on a non-typeable plasmid of 120 kb in six strains from India (four K. pneumoniae, one E. cloacae and one C. freundii) and in three of the six K. pneumoniae from the UK (data not shown). In addition, NDM was found co-resident with two methyltransferases (RmtF plus ArmA, RmtB or RmtC) in various isolates (Figure 3) .
A bla CTX-M gene was detected in 37 of 40 (93%) isolates, while an acquired AmpC gene was detected in 7 of 40 (17.5%) isolates.
Four rmtF-bearing K. pneumoniae were resistant to tigecycline (MICs 4 -16 mg/L) and 14 isolates (10 K. pneumoniae, 2 E. cloacae and 2 E. coli) had intermediate resistance ( Hidalgo et al.
( Table 2 ). Colistin resistance was detected in one K. pneumoniae (4 mg/L) and one E. cloacae (16 mg/L), both isolated in India. The E. cloacae (BB1092) was recovered from sputum and was an NDM producer; its PFGE profile was identical to that of a colistinsusceptible (1 mg/L) and NDM-producing isolate (BB1271) from CSF of a different patient.
Discussion
The 16S rRNA methyltransferases pose a public health threat because they confer broad and high-level resistance to most clinically available aminoglycosides. Some of the 16S rRNA methyltransferases presumably originated as intrinsic, chromosomally encoded enzymes in environmental Actinomycetes, serving to protect these bacteria from the aminoglycosides that they produce. 29 In recent years, however, diverse 16S rRNA methyltransferases have emerged as acquired resistance determinants in several genera of the Enterobacteriaceae and have been detected not only in humans, but also in pets, 30 livestock 31 and food. 16, 32 A new 16S methyltransferase, RmtF, was recently identified in a single K. pneumoniae isolate from La Réunion Island. 5 In this study we found that 14% of consecutive Enterobacteriaceae from an Indian hospital were highly resistant to aminoglycosides and identified many with 16S methyltransferases, of which 34 strains carried RmtF. Many (59%) of these RmtF-positive Indian isolates also contained an NDM carbapenemase, so we screened NDM-positive Enterobacteriaceae from the UK to explore this association further, finding six more RmtF producers.
Galimand et al. 5 deduced that RmtF is a G1405 methyltransferase based on amino acid identity with other G1405 methyltransferases. However, we have demonstrated in this study the mechanism of action of this novel determinant at the molecular level. The overall low level of amino acid identity shared between the 16S rRNA methyltransferases identified in clinical isolates of Gram-negative bacteria and the Actinomycetes suggests further novel 16S rRNA methyltransferases may be identified in clinical isolates in the future.
We identified RmtF in multiple strains of four different bacterial genera located on at least three different plasmid backbones. This diversity suggests that, like NDM carbapenemase, this novel aminoglycoside resistance determinant escaped unrecognized into Enterobacteriaceae some time ago.
Multidrug-resistant organisms, including those expressing resistance to carbapenems, are becoming increasingly prevalent worldwide. The identification of RmtF co-resident in strains harbouring ESBLs, acquired AmpC enzymes, the NDM carbapenemase and fluoroquinolone-resistance mechanisms not only leads to the potential for co-selection and maintenance of resistance by the use of other antibiotics, but also seriously compromises the treatment of life-threatening infections caused by Gram-negative organisms. The majority of RmtF-producing isolates remain susceptible to tigecycline and colistin, as do most strains harbouring NDM enzymes.
14,28 However, we observed clinical resistance to both tigecycline and colistin and intermediate resistance (2 mg/L) to tigecycline among isolates harbouring both RmtF and NDM, as has been previously noted in NDM producers. 28, 33 In conclusion, we identified here the emergence of a novel antimicrobial resistance determinant, RmtF, associated with NDM carbapenemase in Enterobacteriaceae isolated in India and the UK. Collaborative multinational programmes are crucial if further development of antimicrobial resistance is to be delayed.
The nucleotide sequence for the DNA fragment with rmtF cloned in this study has been deposited in GenBank under accession number JQ955744.
